Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cell-Derived vs Egg-Derived Influenza Vaccine Revaccination
NCT00306527Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of TIVc in influenza (8 arms), sponsored by Novartis. Primary endpoint: Number of Subjects Reporting Solicited Adverse Events. Started Sep 2005; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00306527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306527.